Abstract

Background: Antibodies against glutamic acid decarboxylase (GAD) are associated with various neurologic conditions described in patients, including stiff person syndrome, cerebellar ataxia, refractory epilepsy, and limbic and extralimbic encephalitis. There have been some case reports and investigations regarding anti-GAD65 antibody-associated encephalitis in adult populations, but pediatric cases are rare. We retrospectively analyzed the clinical data of three anti-GAD65 antibody-positive patients to explore the diversity and clinical features of anti-GAD65 antibody-associated pediatric autoimmune encephalitis.Methods: The clinical data of a series of three patients positive for anti-GAD65 antibody were retrospectively analyzed. GAD65 antibodies were determined in serum and CSF using a cell-based assay.Results: All three patients were female, and the onset ages were 4 years and 9 months, 6 years, and 16 years old. Their clinical phenotypes included autoimmune limbic encephalitis, extralimbic encephalitis, and encephalitis combining limbic and extralimbic encephalitis. The clinical symptoms included seizures, memory deficits, drowsiness, dysautonomia, and headache. All patients had abnormal carinal MRI and EEG. All patients received immunotherapy and had transiently good responsiveness, but one patient then experienced relapse. In follow-up, one patient with extralimbic encephalitis recovered completely, while two patients with limbic involvement had poor outcomes with refractory focal epilepsy.Conclusion: In addition to limbic encephalitis, extralimbic encephalitis is also an important phenotype in patients who are positive for anti-GAD65 antibodies. Early diagnosis and immunotherapy can improve the symptoms. However, patients with limbic encephalitis often have refractory epilepsy in the chronic phase and have a poor long-term outcome.

Highlights

  • Glutamic acid decarboxylase (GAD), an enzyme that converts the excitatory neurotransmitter glutamic acid to the inhibitory neurotransmitter γ-aminobutyric acid (GABA), is widely distributed within the pancreas, nervous system, and other organs (1)

  • This study was performed in 180 pediatric patients with possible autoimmune encephalitis from January 2018 to January 2020 who were admitted to the Department of Neurology, Beijing Children’s Hospital

  • Three of 180 pediatric patients tested positive for anti-GAD65 Ab in both serum and cerebrospinal fluid (CSF) samples

Read more

Summary

Introduction

Glutamic acid decarboxylase (GAD), an enzyme that converts the excitatory neurotransmitter glutamic acid to the inhibitory neurotransmitter γ-aminobutyric acid (GABA), is widely distributed within the pancreas, nervous system, and other organs (1). Anti-GAD65 antibodies (GAD65-Abs) have been described as biomarkers for type 1 diabetes mellitus and for several neurological syndromes, such as, stiff-person syndrome (SPS), cerebellar ataxia (CA), limbic encephalitis (LE), extralimbic encephalitis (ELE), and drug-resistant epilepsy (EP) (2–4). There have been some case reports and investigations regarding GAD65-Ab-associated encephalitis in adult populations, but pediatric cases were rare, and no cases involving Chinese children had been reported (5–11). We report the first case series of GAD65-Ab-associated encephalitis in Chinese children. Antibodies against glutamic acid decarboxylase (GAD) are associated with various neurologic conditions described in patients, including stiff person syndrome, cerebellar ataxia, refractory epilepsy, and limbic and extralimbic encephalitis. There have been some case reports and investigations regarding anti-GAD65 antibody-associated encephalitis in adult populations, but pediatric cases are rare. We retrospectively analyzed the clinical data of three anti-GAD65 antibody-positive patients to explore the diversity and clinical features of anti-GAD65 antibody-associated pediatric autoimmune encephalitis

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call